pharma · Patency of the Ductus Arteriosus · Atopic Dermatitis · CNTB
S.L
S.L clinical programs — 7 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- SAN DIEGO, CA, EU
- Programs
- 15
- Drugs
- 11
- Patents
- 179
S.L projects
7 ClinicalTrials.gov programs sponsored by S.L.
S.L has 7 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
CBP-201
S.L
Moderate to Severe Persistent Asthma
1 trial -
CBP-201
S.L
Chronic Rhinosinusitis With Nasal Polyps
1 trial -
CBP-201
S.L
Moderate-to-severe Atopic Dermatitis
2 trials -
Double-Blind 0.2mg CBP-307
S.L
Moderate to Severe Ulcerative Colitis
1 trial -
Rademikibart in prefilled syringe
S.L
Asthma Acute
1 trial -
Rademikibart in prefilled syringe
S.L
COPD Acute Exacerbation
1 trial -
umbilical cord blood (hUCB) cells
S.L
Cerebral Palsy
1 trial
Frequently asked questions
How many clinical projects does S.L have?
7 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.